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Microbial fermentation: New tools to 
speed-up vaccine antigen development 




Bioprocess R&D Upstream platform
Vaccine technology IV May 23rd 2012, 
Albufeira, Portugal
2SANOFI PASTEUR : 
The vaccines division of SANOFI group
● World leader in vaccines
● 20 diseases
● More than 1 billion doses/year
● More than 500 million people 
vaccinated/year
● 13 vaccines in development(1)
● Nearly 13,000 employees(2)
● 12 production/R&D sites in the world
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● France (Marcy l’Etoile and Val de Reuil)







And 3 new facilities under construction: Mexico 
(Ocoyoacac), France (Neuville) and China 
(Shenzhen)
1. As of July 28, 2011, from phase I  to “submitted”









Haemophilus influenzae type b Infections 
Meningococcal meningitis
● The site manufactures vaccines against 11 of the 20 diseases that Sanofi Pasteur’s


















































































































































































Different sequential process screening/development platforms
● Tools architecture organized in each platform to speed-up strain selection, 
process development and optimization of industrial processes
SCREENING PLATFORM
for clone selection
PROCESS DEVELOPMENT INDUSTRIAL PROCESS 
OPTIMIZATION
Aerobic & Anaerobic strains
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Process for Phase I/II







µscale and disposable bioreactors for fast material supply












Efficient disposable system for 
microbial production
















Set-up of predictive µscale tools for difficult to express protein
-Shake flask in optimum 
conditions*
-µscale bioreactors  for 
microbial system*
Clones pre-
selection (3-15)                
Commercial or in 
house customized 
media:
-Composition to favor 
Strain selection based 
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on its potential in 
different conditions
*Tools optimized to be representative of 20-200L scale bioreactor performances -
Based on kLa measurement in our culture conditions (media, temperature)
~8 weeks  
Screening platform




● Difficult to solubilize protein for vaccine antigen subunit
● Evaluation of different culture conditions, under induction, for pre-selected functional clones: 
























































● Evaluation of production in the soluble 
and insoluble fractions for each 
condition
● Main results
● Soluble fraction for the protein P1 
expressed in  E. coli Arctic host in a 
specific medium
● No soluble fraction with E. coli BL21 
Screening platform
Case study: screening of different hosts/media






whatever the culture conditions
● Next step: optimize  best clone culture 
conditions to increase the protein 
production in the soluble fraction
Screening platform




● Initial process in stainless steel fermentor (30L scale)
● E.coli strain, protein production induced with IPTG
● Regulations:
• pH: 7.00, 37°C, DO: 30% (cascade: stirrer , air flow then oxygen enrichment)
● Evaluated system for fast preclinical production turn around: Cell tainer system




● Atypical agitation system allowing to reach high Kla values
● Preliminary run performed with working volume at 11 liters :
● Foam in out air filter, Oxygen limitation
● Optimal settings identified via kLa measurement :
● Working volume (7L), stirrer (45 rpm)
● Addition of anti-foam before inoculation
● Angle of agitation fixed at the maximum Max kLa value: 300h-1
Batch mode process performance
● Growth kinetics with optimum 
settings  
● similar growth and biomass between 























BAT 2072 Cell Tainer

































0 1 2 3
Post induction time (hour)
Protein production
BAT 2082 Cell Tainer
BAT 2072 Cell Tainer
FDV 01536
● Protein production analysis by SDS – PAGE / Scan
● Comparable protein expression between Cell Tainer 
and  stainless steel reference
0
0 1 2 3 4 5 6
Time of culture (hour)
● Process parameters and metabolites follow-up:
● Kinetic of glucose consumption identical to our standard process  
● No oxygen limitation but set point not maintained during the culture














% O2 BAT 2072
% O2 BAT 2082
Agitation BAT 2072
Batch mode process performance 7/8



















BAT 2072 Cell Tainer
BAT 2082 Cell Tainer
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● Fed batch process:
● Preliminary work shows than we can maintain DO above 20%























0 1 2 3 4 5 6 7















● First efficient E.coli batch process in a single use bioreactor
● Similar biomass (around 20g/L cdw) and protein production versus standard  fermentor
● Batch and fed batch processes capabilities
● Good reproducibility








● However, system scalability limited for purposes beyond preclinical supplies, seed 
train, phase I GMP production
Microbial fermentation
Different sequential process screening/development platforms
● Tools architecture organized in each platform to speed-up strain selection, 
process development and optimization of industrial processes
SCREENING PLATFORM
for clone selection
PROCESS DEVELOPMENT INDUSTRIAL PROCESS 
OPTIMIZATION
Aerobic & Anaerobic strains
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Process for Phase I/II
Recombinant         Pathogens
Industrial process optimization
Case study: µscale to industrial scale
● Aerobic pathogenic strain – Industrial process
● Aim of the study:
● To model the impact of 3 process parameters (pH, DO, T) on 
biomass and antigen production and impurity level










and improvement of 
culture parameters 
for an industrial 
process
Industrial 











Working volume 150 ml 3 ml 0.5L 30L 1000L
C apacity of fermentors
available in the lab








0.4 0.75 0.8 0.71 0.62
● Effect of  pH on  biomass (T at  37°C , DO2 at 30%)
● Effect of  DO2 on   biomass  (no pH regulation and T at 37°C)
Experimental domain definition :
identification of limit values for each parameter investigated



























Domain fixed for DO2 :
5%  to 70%
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23pH 5,5 pH 6,2 pH 7,00 pH 7,6 pH 7,8 pH 8,0pH 5,9










































25°C 30°C 37°C 40°C 42°C28°C
Domain fixed for T°: 
30°C to 40°C
DOE matrix selection  for the study
Response surface model
(central composite matrix)




• Response surface model 
(central composite matrix)
• 21 cultures 
• 15 conditions for the DOE
• 3 repetitions of  central point
• 4 test points to validate the 
model






















Dissolved O2 fixed at 30%
temperature30°C 35°C 40°C
5.95





Dissolved O2 fixed at 30%
30°C
30°C 35°C 40°C
Significant effects identified :
- pH (+++)
- Interaction pH / DO2 (++)
- Interaction temperature / pH (+)
- DO2 (+)
Significant effects identified :
- temperature (+++)
- pH (++)
- Interaction DO2 / pH (+)
- DO2 (+)
Significant effects identified :
- pH (+++)
- Interaction DO2 / temperature (+)
• Effect of the 3 parameters investigated on the 3 responses (single effect or interaction)
• But no condition allowing at the same time to maximize antigen production and minimize 
the impurity quantity
● Modelisation of the phenomena investigated in the experimental 
domain 
● Compromise  :
Identification  of conditions allowing at the same time the increase of 
the antigen production and the maintain/control impurity level
DOE interpretation and modelisation INDUSTRIAL PROCESS OPTIMIZATION
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Implementation of results obtained 
through the DOE
Confirmation of  results 
obtained with DOE at 
micro scale : 
















OD  max (600nm) 11 12 12 11 11 .5
Product yield 
0.8 1.23 1.26 1.28 1.2 7
● Testing of new settings at intermediary scales (fermentors 1liter and 100 liters) 






production confirmed up 




900 000 800 000 95 0 000 69 0 000 78 0 000
● Technological evolution in the single use domain
● For microbial fermentation new single-use and µscale bioreactors have been recently 
developed than can deal with the high oxygen demand
● Benefits of the single use and µscale bioreactors implementation
● Conduce fast expression system screening to select best host, clone, media, vector for 
antigen production at the expected quality and quantity 
● Generate predictible results at industrial scale thanks to parameters regulation
● Increase process knowledge and robustness through DoE with limited workload
● Reduced time of process development trough downscale, multiple parallel bioreactors
Conclusion
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● Ressource allocated to core expertise instead of non value tasks (cleaning, bioreactor 
decontamination)
● Lead significant increase  of the antigen production for two industrial processes
● Next steps
● Implementation of highthrough-put sample treatment, 













Jean Marc GUILLAUME –Head of 
Bioprocess R&D  USP platform
